Vir Biotechnology Inc
VIRHealthcare|Biotechnology|USA
$9.96
-0.38 (-3.68%)
Tangible Book
$4.89
Earnings Power
$9427.04
Clinical Trials (35)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07128550 A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Viral Hepatitis | P3 | Active | 150 | RCT, Open-label | Tobevibart, Elebsiran, Bulevirtide |
| NCT06903338 A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Viral Hepatitis | P3 | Active | 124 | RCT, Open-label | Tobevibart, Elebsiran |
| NCT07142811 A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Viral Hepatitis | P2 | Active | 100 | RCT, Open-label | Tobevibart, Elebsiran, Bulevirtide |
| NCT05970289 Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients | Chronic Hepatitis B Virus Infection | P2 | Active | 86 | RCT, Open-label | PEG-IFNα, BRII-835 |
| NCT06491563 Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) | For Treatment of Chronic Hepatitis B Virus Infection | P2 | Active | 150 | Open-label | BRII-179, BRII-835 (VIR-2218), PEG-IFNα |
| NCT05461170 SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | Hepatitis D, Chronic | P2 | Active | 95 | RCT, Open-label | VIR-2218, VIR-3434, NRTI |
| NCT05356741 To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | Locally Advanced or Metastatic HER2-Expressing Cancers | P1P2 | Recruiting | 645 | Open-label | VIR-5818, pembrolizumab |
| NCT06960395 Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Solid Tumor Malignancies, EGFR Positive Solid Tumors | P1 | Recruiting | 450 | Open-label | VIR-5525, Pembrolizumab |
| NCT05484206 Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | Hepatic Impairment, Cirrhosis | P1 | Recruiting | 144 | Open-label | VIR-2218, VIR-3434 |
| NCT05997615 Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | Hormone-refractory Prostate Cancer | P1 | Recruiting | 437 | Open-label | VIR-5500 |
| NCT06070051 Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy | Chronic Hepatitis B | P1 | Active | 56 | RCT, Open-label | VRON-0200-AdC6, VRON-0200-AdC7, VIR-2218, VIR-3434 |
| NCT04913675 Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | Covid19 | P3 | Terminated | 1,065 | RCT, Open-label | sotrovimab, sotrovimab, sotrovimab, sotrovimab, Sotrovimab, Sotrovimab, Sotrovimab |
| NCT04501978 ACTIV-3: Therapeutics for Inpatients With COVID-19 | Covid19 | P3 | Completed | 2,753 | RCT, Double-blind | LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814 |
| NCT05780281 VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) | COVID-19 | P3 | Completed | 367 | RCT, Double-blind | VIR-7831, Placebo, Remdesivir |
| NCT04545060 VIR-7831 for the Early Treatment of COVID-19 in Outpatients | Covid19 | P2P3 | Completed | 1,057 | RCT, Double-blind | VIR-7831 (sotrovimab), Placebo |
| NCT04779879 Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 | Covid19 | P2 | Completed | 354 | RCT, Open-label | Sotrovimab (Gen1), Sotrovimab (Gen2), Sotrovimab (Gen2) |
| NCT04856085 Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | Hepatitis B, Chronic | P2 | Completed | 244 | Open-label | VIR-2218, VIR-3434, PEG-IFNα |
| NCT04749368 Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection | Hepatitis B, Chronic | P2 | Completed | 91 | RCT, Open-label | BRII-835 (VIR-2218), BRII-179 (VBI-2601) with IFN-α, BRII-179 (VBI-2601) |
| NCT03672188 Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B | Chronic Hepatitis B | P1P2 | Completed | 82 | RCT, Double-blind | VIR-2218, Placebo |
| NCT04507269 Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China | Hepatitis B, Chronic | P2 | Completed | 21 | RCT, Double-blind | VIR-2218, Placebo |
| NCT04412863 Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P2 | Completed | 84 | Open-label | VIR-2218, pegylated interferon-alfa 2a |
| NCT05567783 A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A | Influenza A | P2 | Terminated | 2,977 | RCT, Double-blind | VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo |
| NCT05612581 A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | Hepatitis B, Chronic | P1P2 | Completed | 33 | Open-label | VIR-3434, VIR-2218, TDF, PEG-IFNα |
| NCT04891770 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | Chronic Hepatitis B | P2 | Completed | 103 | RCT, Open-label | Tenofovir Alafenamide, VIR-2218, Nivolumab, Selgantolimod |
| NCT05124210 Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19 | COVID-19 | P2 | Terminated | 8 | Open-label | Sotrovimab |
| NCT04634409 A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness | COVID-19 | P2 | Completed | 1,755 | RCT, Double-blind | Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab |
| NCT05280717 Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) | Covid19 | P1 | Terminated | 316 | RCT, Open-label | sotrovimab, sotrovimab, sotrovimab, sotrovimab, sotrovimab, sotrovimab, sotrovimab |
| NCT04988152 A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants | Covid19 | P1 | Completed | 48 | RCT, Single-blind | sotrovimab, sotrovimab |
| NCT05844228 A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 | Renal Impairment | P1 | Completed | 28 | Open-label | VIR-2218 |
| NCT04423393 Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P1 | Completed | 113 | RCT, Double-blind | VIR-3434 |
| NCT04033406 Study of VIR-2482 in Healthy Volunteers | Influenza A | P1 | Completed | 100 | RCT, Double-blind | VIR-2482, Placebo |
| NCT04725877 VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers | HIV I Infection | P1 | Completed | 27 | RCT, Double-blind | VIR-1111, Placebo |
| NCT05135650 Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study | COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm | P1 | Terminated | 20 | Open-label | Sotrovimab |
| NCT05235347 Sotrovimab Expanded Access Treatment Protocol (COVID-19) | Covid19 | NO_LONGER_AVAILABLE | — | — | Sotrovimab | |
| NCT04623138 A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections | Covid19, SARS-CoV Infection | Completed | 847 | — | — |